In a report released on September 11, John McNulty from BMO Capital maintained a Buy rating on DuPont de Nemours, with a price target of $107.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
John McNulty has given his Buy rating due to a combination of factors that highlight DuPont de Nemours’ strong potential for growth and value creation. The recent divestiture of the Kevlar/Nomex business is expected to enhance the company’s long-term growth and margin prospects, while also providing greater financial flexibility. Additionally, the settlement of the PFAS litigation in New Jersey removes a significant uncertainty, allowing the company to focus on its core operations.
Furthermore, DuPont’s strategic positioning in high-growth sectors such as water filtration, healthcare, and electronics is expected to drive GDP-plus growth rates with superior margins compared to its peers. The upcoming split of the company into New DuPont and Qnity is anticipated to unlock further value, with the sum-of-the-parts valuation indicating a substantial upside from the current stock price. These elements combined make DuPont an attractive investment opportunity, justifying the Buy rating.
In another report released on September 12, UBS also reiterated a Buy rating on the stock with a $91.00 price target.
Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DD in relation to earlier this year.